[{"id":"523cb57a-001f-4d73-8c81-664052823b24","acronym":"","url":"https://clinicaltrials.gov/study/NCT05757219","created_at":"2023-03-07T18:02:49.882Z","updated_at":"2024-07-02T16:34:38.016Z","phase":"Phase 2","brief_title":"Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy","source_id_and_acronym":"NCT05757219","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" JAK1 • CRP","pipe":"","alterations":" ","tags":["JAK1 • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yescarta (axicabtagene ciloleucel) • itacitinib (INCB039110)"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 05/19/2023","start_date":" 05/19/2023","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-06-05"},{"id":"782accc5-d280-4011-b282-a7d44c7401ad","acronym":"haplo-HCT","url":"https://clinicaltrials.gov/study/NCT03755414","created_at":"2022-05-12T21:54:02.090Z","updated_at":"2024-07-02T16:35:15.228Z","phase":"Phase 1","brief_title":"Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation","source_id_and_acronym":"NCT03755414 - haplo-HCT","lead_sponsor":"Washington University School of Medicine","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e itacitinib (INCB039110)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 09/04/2019","start_date":" 09/04/2019","primary_txt":" Primary completion: 06/17/2024","primary_completion_date":" 06/17/2024","study_txt":" Completion: 09/05/2024","study_completion_date":" 09/05/2024","last_update_posted":"2024-03-12"},{"id":"14f82f5c-e429-4d17-9a3b-88bdc7d125c9","acronym":"ROME","url":"https://clinicaltrials.gov/study/NCT04591431","created_at":"2021-01-19T20:28:32.767Z","updated_at":"2025-02-25T13:53:27.554Z","phase":"Phase 2","brief_title":"The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy","source_id_and_acronym":"NCT04591431 - ROME","lead_sponsor":"Fondazione per la Medicina Personalizzata","biomarkers":" PD-L1 • BRAF","pipe":"","alterations":" ","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Tecentriq (atezolizumab) • erlotinib • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Rozlytrek (entrectinib) • everolimus • lapatinib • Alecensa (alectinib) • Perjeta (pertuzumab) • Iclusig (ponatinib) • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • Talzenna (talazoparib) • Piqray (alpelisib) • Retevmo (selpercatinib) • Alunbrig (brigatinib) • Gavreto (pralsetinib) • Pemazyre (pemigatinib) • ipatasertib (RG7440) • Tepmetko (tepotinib) • itacitinib (INCB039110)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 10/07/2020","start_date":" 10/07/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-10-03"},{"id":"13897862-4c02-48ae-ae66-7b8e616b8340","acronym":"","url":"https://clinicaltrials.gov/study/NCT02646748","created_at":"2021-01-18T12:52:44.723Z","updated_at":"2024-07-02T16:36:14.414Z","phase":"Phase 1","brief_title":"Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors","source_id_and_acronym":"NCT02646748","lead_sponsor":"Incyte Corporation","biomarkers":" EGFR • ALK • FOXP3","pipe":" | ","alterations":" EGFR mutation • ALK translocation","tags":["EGFR • ALK • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • parsaclisib (INCB50465) • itacitinib (INCB039110)"],"overall_status":"Completed","enrollment":" Enrollment 159","initiation":"Initiation: 01/25/2016","start_date":" 01/25/2016","primary_txt":" Primary completion: 11/07/2019","primary_completion_date":" 11/07/2019","study_txt":" Completion: 11/20/2020","study_completion_date":" 11/20/2020","last_update_posted":"2022-03-31"},{"id":"ba06b0b9-e16a-4394-a355-52120580bc3f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02355431","created_at":"2021-01-18T11:12:30.642Z","updated_at":"2024-07-02T16:37:02.111Z","phase":"Phase 2","brief_title":"Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations","source_id_and_acronym":"NCT02355431","lead_sponsor":"Incyte Corporation","biomarkers":" EGFR • CRP","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • itacitinib (INCB039110)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2014","start_date":" 12/01/2014","primary_txt":" Primary completion: 09/01/2015","primary_completion_date":" 09/01/2015","study_txt":" Completion: 09/01/2015","study_completion_date":" 09/01/2015","last_update_posted":"2019-03-08"}]